Halmos B - Search Results

1

Sunitinib activates Axl signaling in renal cell cancer.

van der Mijn JC, Broxterman HJ, Knol JC, Piersma SR, De Haas RR, Dekker H, Pham TV, Van Beusechem VW, Halmos B, Mier JW, Jiménez CR, Verheul HM. van der Mijn JC, et al. Among authors: halmos b. Int J Cancer. 2016 Jun 15;138(12):3002-10. doi: 10.1002/ijc.30022. Epub 2016 Mar 1. Int J Cancer. 2016. PMID: 26815723 Free article.

2

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B. Kobayashi S, et al. Among authors: halmos b. Cancer Res. 2005 Aug 15;65(16):7096-101. doi: 10.1158/0008-5472.CAN-05-1346. Cancer Res. 2005. PMID: 16103058

3

Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.

Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B. Kobayashi S, et al. Among authors: halmos b. Cancer Res. 2006 Dec 1;66(23):11389-98. doi: 10.1158/0008-5472.CAN-06-2318. Cancer Res. 2006. PMID: 17145885

4

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.

Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV. Naumov GN, et al. Among authors: halmos b. Clin Cancer Res. 2009 May 15;15(10):3484-94. doi: 10.1158/1078-0432.CCR-08-2904. Epub 2009 May 15. Clin Cancer Res. 2009. PMID: 19447865 Free PMC article.

5

Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer.

Kluge A, Dabir S, Kern J, Nethery D, Halmos B, Ma P, Dowlati A. Kluge A, et al. Among authors: halmos b. Int J Cancer. 2009 Oct 1;125(7):1728-34. doi: 10.1002/ijc.24553. Int J Cancer. 2009. PMID: 19569236 Free PMC article.

6

PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status.

Dabir S, Kluge A, McColl K, Liu Y, Lam M, Halmos B, Wildey G, Dowlati A. Dabir S, et al. Among authors: halmos b. Int J Cancer. 2014 Mar 1;134(5):1045-54. doi: 10.1002/ijc.28448. Epub 2013 Sep 23. Int J Cancer. 2014. PMID: 23959540 Free PMC article.

7

AXL kinase as a novel target for cancer therapy.

Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B. Wu X, et al. Among authors: halmos b. Oncotarget. 2014 Oct 30;5(20):9546-63. doi: 10.18632/oncotarget.2542. Oncotarget. 2014. PMID: 25337673 Free PMC article. Review.

8

New twists in the AXL(e) of tumor progression.

Halmos B, Haura EB. Halmos B, et al. Sci Signal. 2016 Oct 4;9(448):fs14. doi: 10.1126/scisignal.aai7619. Sci Signal. 2016. PMID: 27703029 Review.

9

Down-regulation and antiproliferative role of C/EBPalpha in lung cancer.

Halmos B, Huettner CS, Kocher O, Ferenczi K, Karp DD, Tenen DG. Halmos B, et al. Cancer Res. 2002 Jan 15;62(2):528-34. Cancer Res. 2002. PMID: 11809705

10

A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancer.

Halmos B, Bassères DS, Monti S, D'Aló F, Dayaram T, Ferenczi K, Wouters BJ, Huettner CS, Golub TR, Tenen DG. Halmos B, et al. Cancer Res. 2004 Jun 15;64(12):4137-47. doi: 10.1158/0008-5472.CAN-03-4052. Cancer Res. 2004. PMID: 15205324

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

217 results

Search Page